University of Oxford and AstraZeneca’s vaccine plan

SARS-CoV-2

ChAdOx1

A modified chimpanzee adenovirus was chosen to deliver the vaccine

 

It can’t replicate in humans, causing ongoing infection, and has been shown to create a strong immune response from one dose in other vaccines

The coronavirus is so-called due to its spike proteins

 

Studies show that these are a good target for the vaccine

The genes which code for the spikes are identified

This genetic sequence is spliced with the ChAdOx1 construct, creating the vaccine

When the ChAdOx1 construct infects human cells, they produce the spike protein, inducing an immune response

The immune system is now primed to attack a Covid-19 infection

Around 50,000 people are enrolled in combined phase 2/3 and phase 3 trials of the vaccine in the UK, US, South Africa and Brazil

 

The group said they may be able to present data from trials to regulators before the end of 2020

ChAdOx1

SARS-CoV-2

A modified chimpanzee adenovirus was chosen to deliver the vaccine

 

It can’t replicate in humans, causing ongoing infection, and has been shown to create a strong immune response from one dose in other vaccines

The coronavirus is so-called due to its spike proteins

 

Studies show that these are a good target for the vaccine

The genes which

code for the spikes

are identified

This genetic sequence is spliced with the ChAdOx1 construct, creating the vaccine

When the ChAdOx1 construct infects human cells, they produce the spike protein, inducing an immune response

The immune system is now primed to attack a Covid-19 infection

Around 50,000 people are enrolled in combined phase 2/3 and phase 3 trials of the vaccine in the UK, US, South Africa and Brazil

The group said they may be able to present data from trials to regulators before the end of 2020